03 Oct '23
Sight Sciences Announces New, Large-Scale MIGS Data from 41st Congress of ESCRS Demonstrating TCOR™ Using OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma
Efficacy of the Three Most Commonly Used MIGS Technologies plus Cataract Surgery and Cataract Surgery Alone Were Evaluated and Compared in over 100,000 Glaucoma Patient Eyes MENLO PARK, Calif., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences”), an eyecare
11 Sep '23
Sight Sciences Appoints Matt Link as Chief Commercial Officer
Former NuVasive President helped scale high growth medical device company to over $1 billion in revenue MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and
20 Jul '23
Sight Sciences Announces Positive Results and Primary Endpoint Successfully Met in SAHARA, a Randomized Controlled Clinical Trial Comparing Interventional Eyelid Procedures Enabled by TearCare® Technology to Restasis¹ for the Treatment of Dry Eye
Dry eye has significant negative impact on visual function including reading, driving, workplace productivity, physical functioning, and quality of life, and creates a substantial burden to patients and society in general² MENLO PARK, Calif., July 20, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc.
09 Jun '23
Sight Sciences Announces Addition of New Director Catherine Mazzacco
MENLO PARK, Calif., June 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients’ lives, today announces that Catherine Mazzacco was
23 May '23
Sight Sciences Two Year Multicenter Study Results Show Sustained Reductions in Both Intraocular Pressure and Glaucoma Medication Use in Mild-Moderate Primary Open Angle Glaucoma Patients Treated with a Procedure Enabled with the OMNI® Surgical System
Retrospective Clinical Data from Seven US Sites Published in Clinical Ophthalmology Sustained and clinically meaningful IOP reductions observed at 12 months persisted through 24 months Sustained and clinically meaningful reductions in glaucoma medication use observed at 12 months also persisted
Displaying 1 - 10 of 24